Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

Klotho Neurosciences ( ($KLTO) ) has provided an announcement. On July 10, 2025, Klotho Neurosciences announced that the FDA granted Orphan Drug ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical ...

Klotho Neurosciences, Inc., a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies, announced that it is moving forward with manufacturing and ...

Detailed price information for Klotho Neurosciences Inc (KLTO-Q) from The Globe and Mail including charting and trades.